Personalised pathology
- Introduction: Personalised pathology
- Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
- Molecular selection of therapy in colorectal cancer: COIN and FOCUS 3 trials
- Prognostic and predictive value of KRAS and BRAF mutation status and its heterogeneous nature in aCRC
- Predicting benefit from anti-VEGF therapy
- Prognostic significance of MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy
- Novel mutations in the K-Ras oncogene: implications for personalised medicine in the treatment of colorectal cancer
- The detailed molecular analysis of formalin-fixed paraffin embedded (FFPE) wild-type or mutant KRAS colorectal primaries with the aims of identifying transcripts and pathways of relevance to Cetuximab sensitivity and/or KRAS mutational status
